Diagnostic Performance of Plasma p-Tau Biomarkers for Alzheimer's Disease: A Meta-Analysis

Data Sheet 1 from a network meta-analysis by Xiaofen Chen, last updated June 2026. The dataset aggregates results from 18 high-quality studies comprising 24 independent datasets and 4,736 participants. It compares the diagnostic accuracy of plasma phosphorylated tau isoforms (p-tau217, p-tau181, p-tau231) against cerebrospinal fluid or PET standards for detecting Alzheimer's disease pathology.

Use Cases

• Compare diagnostic accuracy (AUC) of different p-tau isoforms and analytical platforms based on the reported P-scores.
• Evaluate the incremental value of p-tau/Aβ42 ratios for amyloid pathology detection as described in the results.
• Assess biomarker performance for disease staging and predicting MCI-to-dementia conversion based on the study findings.
• Analyze the consistency of p-tau217 performance across Han Chinese and Western cohorts as mentioned in subgroup analyses.

Strengths

• Aggregates data from 18 high-quality studies with 4,736 participants, providing a substantial evidence base.
• Includes rigorous screening for statistical independence, selecting the most comprehensive dataset per overlapping cohort.
• Reports specific performance metrics like P-scores and AUC gains with confidence intervals, allowing for quantitative comparison.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment for specific analytical tasks.
• The dataset is small (59.8 KB), indicating it contains summary or aggregated results rather than raw patient-level data.

Provenance

Source

Xiaofen Chen via figshare.

Collection Method

Systematic review and network meta-analysis of published studies.

Freshness

Last updated 2026-06-03 06:45:12; freshness should be verified.

Geography

Includes data from Han Chinese and Western cohorts.